Evidence map›Paper›PMID 40916526›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2025

[A risk prediction model for prognosis and immunotherapy response in prostate cancer patients based on immunosuppressive neutrophil Neu_2 subsets].

Zixian Chen, Jiawei Zhou, Lei Tan, Zhipeng Huang, Kangyi Xue, Mingkun Chen

Abstract readEnglish Abstract
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zixian ChenDepartment of Urology, Third Affiliated Hospital of Southern Medical University, Guangzhou 510000, China.
Jiawei ZhouDepartment of Urology, Third Affiliated Hospital of Southern Medical University, Guangzhou 510000, China.
Lei TanDepartment of Urology, Third Affiliated Hospital of Southern Medical University, Guangzhou 510000, China.
Zhipeng HuangDepartment of Urology, Third Affiliated Hospital of Southern Medical University, Guangzhou 510000, China.
Kangyi XueDepartment of Urology, Third Affiliated Hospital of Southern Medical University, Guangzhou 510000, China.
Mingkun ChenDepartment of Urology, Third Affiliated Hospital of Southern Medical University, Guangzhou 510000, China.

Funding

National Natural Science Foundation of China 81772257 and 81602248
6 · The paper itself

Abstract

objectivesTo identify immunosuppressive neutrophil subsets in patients with prostate cancer (PCa) and construct a risk prediction model for prognosis and immunotherapy response of the patients based on these neutrophil subsets.

methodsSingle-cell and transcriptome data from PCa patients were collected from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). Neutrophil subsets in PCa were identified through unsupervised clustering, and their biological functions and effects on immune regulation were analyzed by functional enrichment, cell interaction, and pseudo-time series analyses. Lasso-Cox regression was utilized to construct a prognostic risk model based on the immunosuppressive neutrophil subsets, and survival analysis and ROC curve analysis were used to compare the prognosis of PCa patients with high and low risks stratified using this model. The relationship of the prognostic risk model with PCa immune infiltration and immune response was evaluated using CIBERSORT and TIDE scores.

resultsPCa tissues showed a significantly greater proportion of infiltrating neutrophils than the adjacent normal tissues (

conclusionsPCa-associated neutrophils are highly heterogeneous. The prognostic risk model constructed based on the immunosuppressive neutrophil Neu_2 subset can effectively predict both the survival outcomes and immune response of PCa patients

Indexed as

ImmunotherapyNeutrophilsProstatic NeoplasmsHumansMalePrognosisneutrophilsprostate cancersingle-cell RNA sequencingtranscriptomicstumor microenvironment

Identifiers

PMID40916526
PMCPMC12415569

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.